Skip to content

Participate in our active studies Subscribe to our Mailing List

AB Science

Masitinib and AB8939 – Two compounds with breakthrough mechanism of action

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Search:

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment

You are here:

Home
News
2018
Masitinib phase 3 study in…

22/10/2018 – Final results will be available in 2019.

Post navigation

PreviousPrevious post:Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis NextNext post:Patients

Related Posts

Update on the restructuring of the AB Science clinical development department in 2018
December 19, 2018

Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral Sclerosis
October 8, 2018

First half of 2018 revenues
October 1, 2018

Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
July 23, 2018

Results of the Combined General Shareholders’ Meeting held on June 29 2018
July 3, 2018

Combined General Shareholders’ Meeting held on June 29, 2018
July 3, 2018

Search

Search:

Recent Posts

AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
Summary of the live webcast held on March 4, 2024, providing an update on AB Science development
Two financial analysis firms initiate coverage of AB Science
AB Science webcast of March 4, 2024
Live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

© AB Science – All right reserved